ATP ion channel-type P2X purinergic receptors as a key regulatory molecule in breast cancer progression

IF 3.2 4区医学 Q2 PATHOLOGY Pathology, research and practice Pub Date : 2025-03-01 Epub Date: 2025-02-14 DOI:10.1016/j.prp.2025.155844

Xin-Hua Nie , Teng-Zheng Li , Cheng-Ming Peng

{"title":"ATP ion channel-type P2X purinergic receptors as a key regulatory molecule in breast cancer progression","authors":"Xin-Hua Nie , Teng-Zheng Li , Cheng-Ming Peng","doi":"10.1016/j.prp.2025.155844","DOIUrl":null,"url":null,"abstract":"<div><div>Studies have confirmed that ATP ion channel P2X purinergic receptors play a key role in tumor growth and metastasis. Similarly, P2X purinergic receptors can be used as a favorable regulatory molecule of breast cancer cells to participate in the progression of breast cancer. There are abundant ATP and its cleavage products in breast cancer microenvironment, which can be used as natural activators of P2X purinergic receptors. P2X purinergic receptors play a role in regulating the growth and metastasis of breast cancer cells by mediating signal transduction, growth regulation and immune cell activity in microenvironment. However, the application of P2X purinergic receptors antagonist has the pharmacological characteristics of inhibiting the progression of breast cancer cells. Among P2X purinergic receptors, there is a close relationship between P2X7 receptor and breast cancer patients. P2X purinergic receptors can be used as a biological marker for breast cancer patients. In this paper, we discuss the functional role and regulatory molecular mechanism of P2X purinergic receptors in the progression of breast cancer. The pharmacological effects of P2X purinergic receptors selective antagonist on the growth, metastasis and invasion of breast cancer cells were further discussed. Therefore, P2X purinergic receptors can be used as a key regulatory molecule of breast cancer and a pharmacological target for potential therapy.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"267 ","pages":"Article 155844"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology, research and practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0344033825000366","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Studies have confirmed that ATP ion channel P2X purinergic receptors play a key role in tumor growth and metastasis. Similarly, P2X purinergic receptors can be used as a favorable regulatory molecule of breast cancer cells to participate in the progression of breast cancer. There are abundant ATP and its cleavage products in breast cancer microenvironment, which can be used as natural activators of P2X purinergic receptors. P2X purinergic receptors play a role in regulating the growth and metastasis of breast cancer cells by mediating signal transduction, growth regulation and immune cell activity in microenvironment. However, the application of P2X purinergic receptors antagonist has the pharmacological characteristics of inhibiting the progression of breast cancer cells. Among P2X purinergic receptors, there is a close relationship between P2X7 receptor and breast cancer patients. P2X purinergic receptors can be used as a biological marker for breast cancer patients. In this paper, we discuss the functional role and regulatory molecular mechanism of P2X purinergic receptors in the progression of breast cancer. The pharmacological effects of P2X purinergic receptors selective antagonist on the growth, metastasis and invasion of breast cancer cells were further discussed. Therefore, P2X purinergic receptors can be used as a key regulatory molecule of breast cancer and a pharmacological target for potential therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

ATP离子通道型P2X嘌呤能受体在乳腺癌进展中的关键调控分子

研究证实ATP离子通道P2X嘌呤能受体在肿瘤生长和转移中起关键作用。同样，P2X嘌呤能受体可以作为乳腺癌细胞的有利调控分子参与乳腺癌的进展。乳腺癌微环境中存在丰富的ATP及其裂解产物，可作为P2X嘌呤能受体的天然激活剂。P2X嘌呤能受体在微环境中通过介导信号转导、生长调节和免疫细胞活性等途径，调控乳腺癌细胞的生长和转移。而P2X嘌呤能受体拮抗剂的应用具有抑制乳腺癌细胞进展的药理特性。在P2X嘌呤能受体中，P2X7受体与乳腺癌患者关系密切。P2X嘌呤能受体可作为乳腺癌患者的生物学标志物。本文就P2X嘌呤能受体在乳腺癌进展中的功能作用及调控分子机制进行探讨。进一步探讨P2X嘌呤能受体选择性拮抗剂对乳腺癌细胞生长、转移和侵袭的药理作用。因此，P2X嘌呤能受体可以作为乳腺癌的关键调控分子和潜在治疗的药理学靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pathology, research and practice 医学-病理学

CiteScore

5.00

自引率

3.60%

发文量

405

审稿时长

24 days

期刊介绍： Pathology, Research and Practice provides accessible coverage of the most recent developments across the entire field of pathology: Reviews focus on recent progress in pathology, while Comments look at interesting current problems and at hypotheses for future developments in pathology. Original Papers present novel findings on all aspects of general, anatomic and molecular pathology. Rapid Communications inform readers on preliminary findings that may be relevant for further studies and need to be communicated quickly. Teaching Cases look at new aspects or special diagnostic problems of diseases and at case reports relevant for the pathologist''s practice.